Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients

Annals of Oncology

Volumn 9, Issue 12, 1998, Pages 1351-1353

  Zinzani, P L ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Gemcitabine; Mycosis fungoides; Peripheral T cell lymphoma; Skin involvement

Indexed keywords

ALPHA INTERFERON; BLEOMYCIN A2; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; IDARUBICIN; MITOXANTRONE; PENTOSTATIN; PREDNISONE; PSORALEN; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; MYCOSIS FUNGOIDES; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PUVA; T CELL LYMPHOMA; THROMBOCYTOPENIA;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LYMPHOMA, T-CELL, PERIPHERAL; MALE; MIDDLE AGED; MYCOSIS FUNGOIDES; NEUTROPENIA; PUVA THERAPY; REMISSION INDUCTION; SAFETY; SALVAGE THERAPY; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0032435867     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008409601731     Document Type: Article

References (12)

1. Harris N, Jaffe E, Stein H et al. A revised European-American Classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361-92.
2. Winkler CF, Sausville EA, Ihde DC et al. Combined modality treatment of cutaneous T cell lymphoma: Results of a six-year follow-up. J Clin Oncol 1986; 4:1094-100.
3. Ascani S, Zinzani PL, Gherlinzoni F et al. Peripheral T-cell lymphomas. Clinico-pathologic study of 168 cases diagnosed according to the R.E.A.L. Classification. Ann Oncol 1997; 8: 583-92.
4. Ansell SM, Habermann TM, Kurtin PJ et al. Predictive capacity of the International Prognostic Factor Index in patients with peripheral T-cell lymphoma. J Clin Oncol 1997; 15: 2296-301.
5. Polplin HAD, Corbett T, Flaherty L et al. Difluorodeoxycytidine (dFdC, gemcitabine): A phase I study. Invest New Drugs 1992; 10: 165-70.
6. Abbruzzese JL, Grunewald R, Weeks EA et al. A phase I clinical, plasma and cellular pharmacology study of gemcitabine. J Clin Oncol 1991; 9: 491-8.
7. International Union against Cancer (UICC). TNM Classification of Malignant Tumours. New York: Springer-Verlag 1987.
8. Carbone PP, Kaplan HS, Musshoff K. Report of committee on Hodgkin's disease staging classification. Cancer 1971; 31: 1860-1.
9. Santoro A, Devizzi L, Bonfante V et al. Phase II study with gemcitabine in pretreated patients with Hodgkin's (HD) and nonHodgkin's lymphomas (NHL): Results of a multicenter study. Blood 1997; 89 (Suppl 1): 71.
10. Von Hoff DD, Dahlberg S, Hartstock RJ, Eyre HJ. Activity of fludarabine monophosphate in patients with advanced mycosis fungoides: A Southwest Oncology Group Study. J Natl Cancer Inst 1990; 82:1353-5.
11. Huang P, Plunkett W. Fludarabine- and gemcitabine-induced apoptosis: Incorporation of analogs into DNA is a critical event. Cancer Chemother Pharmacol 1995; 36:181-8.
12. Iwasaki H, Huang P, Keating MJ, Plunkett W. Differential incorporation of ara-C, gemcitabine, and fludarabine into replicating and repairing DNA in proliferating human leukemia cells. Blood 1997; 90: 270-8.